Repotrectinib (TPX-0005), Effectively Reduces Growth of ALK Driven Neuroblastoma Cells

Scientific Reports - United Kingdom
doi 10.1038/s41598-019-55060-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

OA09 Preliminary Clinical Activity of Repotrectinib (TPX-0005) in Advanced ROS1 Fusion-Positive Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

OA02.02 Safety and Preliminary Clinical Activity of Ropotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

NeuroD1 Promotes Neuroblastoma Cell Growth by Inducing the Expression of ALK

Cancer Science
Cancer ResearchMedicineOncology
2015English

ALK and GSK3: Shared Features of Neuroblastoma and Neural Crest Cells

Journal of Experimental Neuroscience
Neuroscience
2018English

The ALK Inhibitor PF-06463922 Is Effective as a Single Agent in Neuroblastoma Driven by Expression of ALK and MYCN

DMM Disease Models and Mechanisms
ImmunologyMolecular BiologyBiochemistryMicrobiology NeuroscienceMedicineGenetics
2016English

Flotillin-1 Regulates Oncogenic Signaling in Neuroblastoma Cells by Regulating ALK Membrane Association

Cancer Research
Cancer ResearchOncology
2014English

ALK in Neuroblastoma: Biological and Therapeutic Implications

Cancers
Cancer ResearchOncology
2018English

Aberrant Activation of ALK Kinase by a Novel Truncated Form ALK Protein in Neuroblastoma

Oncogene
Cancer ResearchGeneticsMolecular Biology
2012English

P565 Validation of Novel Growth-Promoting and Growth-Suppressing Genes in Neuroblastoma Cells

2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy